Clinical Trials Logo

Clinical Trial Summary

The investigators will assess the efficacy of clinically recommended counterpressure maneuvers (CPM) in preventing syncope for paediatric patients. Participants presenting to the emergency department (ED) will first provide written informed consent. In stage I, they will be asked to complete a brief survey documenting the presentation of their syncopal episode, and any prodromal symptoms they experienced. Participants that consent to the second stage of the study will either receive usual care (control arm) or training in counter pressure maneuvers alongside usual care (intervention arm; leg crossing, bending, arm tensing). These patients will be followed for one years time, and will be asked to complete monthly surveys detailing their syncopal and presyncopal recurrence. Medical records will be accessed over the duration of the study to identify any changes in medical diagnosis.


Clinical Trial Description

Knowledge Gaps and Objectives The typical presentation and management for paediatric syncope is poorly understood. From research in adults, it is known that obtaining a detailed history of prodromal symptoms and the circumstance of a syncopal event is important for diagnosis, risk stratification, and determining patient prognosis. However, research in paediatric patients is lacking, with recommendations often disputed and based on a paucity of direct evidence, assuming that children will respond similarly to adults; however, this may not be the case. The investigators will (stage I) catalogue the syncopal symptoms observed in paediatric patients presenting to the emergency department (ED) with transient loss of consciousness, and (stage II) assess the efficacy of counter pressure maneuver (CPM) training in preventing recurrent syncope for paediatric patients. Methods, Stage I; Presentation of syncope in paediatric patients Ethical approval for this study was granted by the University of British Columbia's Clinical Research Ethics Board. The investigators will recruit paediatric patients (age 7-19 years) presenting to the ED with resolved transient loss of consciousness in the last week. Research assistants will identify potential participants based on exclusion criteria, and a clinician will later gather a brief medical history and perform a screen for study eligibility. Exclusion criteria: suspected or confirmed cardiac arrhythmia diagnosis; traumatic head injury; new presentation of a seizure disorder or epilepsy; structural heart disease; hypoglycemia; physical and/or psychological disability associated with vasovagal syncope (VVS). Consenting patients will complete a survey detailing the nature of their episodes in terms of the provocative situation, their signs and symptoms, and history of syncope or presyncope alongside a brief medical history (age, self-reported Tanner stage, age at onset of female menarche if applicable). The primary outcome is to document the typical presentation of syncope and presyncope in paediatric patients identified as having experienced VVS. Additional outcomes include predictive factors for uncomplicated syncope in this population, including the influence of pubertal stage on the onset of paediatric syncope. Secondary outcomes include identifying the incidence of syncope, determining typical causes for syncope, and reporting on predictive factors for syncope secondary to other causes in this population. Bivariate analyses assessing possible associations between presenting prodromes and syncopal diagnoses will be conducted using either Fisher or Chi-square tests for categorical variables, and univariate multinomial models for continuous variables. These analyses will also be conducted adjusting for age and sex (either through regression or matching). The incidence and subtype of syncope presented will be calculated using an appropriate reference population. Qualitative data will be analyzed using a thematic approach, to identify trends in chosen variables based on patient responses. Methods, Stage II; Paediatric counterpressure manoeuvres trial Stage I patients with a confirmed diagnosis of VVS from a clinician will be referred to stage II. Patients will be followed for one year while they implement either usual care for syncope (behavioural interventions and avoidance measures) or usual care alongside CPM use (leg crossing, hand grip, crouching). The primary outcome measure will be the time to syncopal reoccurrence over the 1-year follow up period, while secondary outcome measures include history of syncope in the prior 2 years, frequency of presyncopal episodes, preferred management strategies (CPM, or usual care), and barriers to implementing CPM. The predicted risk of syncopal reoccurrence will be identified using a logistic regression model with a covariate for treatment arm (CPM, standard of care). Outcomes will be compared between groups using the estimated risk ratio and risk difference. The Wald test for the log-odds coefficient from the logistic model will be used to test for treatment effect (level of 0.05). The investigators will also perform a Kaplan-Meier survival analysis (time to syncope recurrence), using a log-rank test and Cox proportional hazards analysis to compare curves. Qualitative follow-up call data will again be analyzed using a thematic approach. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05555771
Study type Interventional
Source Simon Fraser University
Contact Erin L Williams, BSc
Phone 6048976372
Email erin_williams_2@sfu.ca
Status Recruiting
Phase N/A
Start date September 3, 2022
Completion date September 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05923840 - Chemoreflex and Baroreflex Alterations Causing Postural Tachycardia Syndrome With Orthostatic Hyperpnea and Hypocapnia N/A
Completed NCT05633407 - Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS Phase 2
Completed NCT03930914 - Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome N/A
Recruiting NCT00865917 - Cardiovascular Effects of Selective I(f)-Channel Blockade Phase 2
Recruiting NCT05741112 - The Long COVID-19 Wearable Device Study N/A
Recruiting NCT05454137 - A Shared Medical Appointment Intervention for Quality of Life Improvement in POTS N/A
Recruiting NCT05924646 - CAlgary SAlt for POTS N/A
Enrolling by invitation NCT05877534 - Effects of Individual Tailored Physical Exercise in Patients With POTS After COVID-19 - a Randomized Controlled Study N/A
Recruiting NCT06268288 - Non-invasive Vagal Neurostimulation (nVNS) in Adolescents With Postural Orthostatic Tachycardia Syndrome (POTS) N/A
Completed NCT01367977 - Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia Later in Life
Recruiting NCT04881318 - Compression Garments in the Community With POTS N/A
Recruiting NCT06292104 - Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)
Completed NCT02171988 - Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) Phase 4
Completed NCT01617616 - Tilt Table With Suspected Postural Orthostatic Tachycardia Syndrome (POTS) Subjects N/A
Completed NCT01547117 - Dietary Salt in Postural Tachycardia Syndrome N/A
Completed NCT01563107 - Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome N/A
Active, not recruiting NCT02281097 - Transdermal Vagal Stimulation for POTS N/A
Completed NCT00728026 - Autonomic Profiles in Pediatric Patients With Cyclic Vomiting Syndrome (CVS), Irritable Bowel Syndrome (IBS),Postural Orthostatic Tachycardia Syndrome (POTS), Functional Abdominal Pain (FAP) or Chronic Nausea N/A
Recruiting NCT05481177 - Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort Phase 4
Not yet recruiting NCT05914649 - NC Testing in LC & POTS N/A